Top

Published in:

01-12-2020 | Cardiac Tumor | Original research

Combined PET/CT with thoracic contrast-enhanced CT in assessment of primary cardiac tumors in adult patients

Authors: En-Tao Liu, Tao-Tao Sun, Hao-Jian Dong, Si-Yun Wang, Ze-Rui Chen, Chao Liu, Dan Shao, Zhou-Yang Lian, Qiu Xie, Shu-Xia Wang

Published in: EJNMMI Research | Issue 1/2020

Abstract

Background

¹⁸F-FDG PET/CT is a key molecular imaging modality to noninvasively assess and differentiate benign and malignant cardiac tumors. However, few benign cardiac tumors can be characterized by increased ¹⁸F-FDG uptake, which makes differential diagnosis difficult. This study sought to retrospectively evaluate whether combined ¹⁸F-FDG PET/CT with thoracic contrast-enhanced CT (CECT) helps in assessing primary cardiac tumors in adult patients, compared with CECT or PET/CT alone.

Methods

Forty-six consecutive patients who were diagnosed as primary cardiac tumors were enrolled. All patients underwent ¹⁸F-FDG PET/CT followed by thoracic CECT before biopsy or surgery. Visual qualitative interpretation and quantitative analysis were performed, and diagnostic performance was evaluated.

Results

More than half (16/29) of benign tumors exhibited with mild ¹⁸F-FDG uptake. There were significant differences in ¹⁸F-FDG uptake and the degree of absolute enhancement between benign and malignant tumors (P < 0.001). The combination of two modalities improved the specificity from 79 to 93%, the positive predictive value from 73 to 89%, and the accuracy of diagnosis from 85 to 93%. There were significant differences between PET/CT alone or thoracic CECT alone and combined modalities (P = 0.034 and P = 0.026, respectively). The combination with the optimal SUVmax cutoff value generated 94% sensitivity, 100% specificity, 97% negative predictive values, 100% positive predictive values, and 98% accuracy rates.

Conclusions

Combining ¹⁸F-FDG PET/C with thoracic CECT significantly improved specificity and accuracy compared to CECT or PET/CT alone in detecting tumors. This combination of diagnostic imaging is effective in differentiating malignant from benign masses.

Available only for authorised users

Reynen K. Cardiac myxomas. N Engl J Med. 1995;333:1610–7. https://doi.org/10.1056/NEJM199512143332407.

Reynen K. Frequency of primary tumors of the heart. Am J Cardiol. 1996;77:107.

Shapiro LM. Cardiac tumours: diagnosis and management. Heart. 2001;85:218–22.

Rahbar K, Seifarth H, Schäfers M, Stegger L, Hoffmeier A, Spieker T, et al. Differentiation of malignant and benign cardiac tumors using ¹⁸F-FDG PET/CT. J Nucl Med. 2012;53:856–63. https://doi.org/10.2967/jnumed.111.095364.

Gheysens O, Cornillie J, Voigt JU, Bogaert J, Westhovens R. Left atrial myxoma on FDG-PET/CT. Clin Nucl Med. 2013;38:e421–2. https://doi.org/10.1097/RLU.0b013e31827086a3.

Okazaki Y, Yamada S, Kitada S, Matsunaga I, Nogami E, Watanabe T, et al. Significance of ¹⁸F-FDG PET and immunohistochemical GLUT-1 expression for cardiac myxoma. Diagn Pathol. 2014;9:117. https://doi.org/10.1186/1746-1596-9-117.

You SC, Shim CY, Kim JJ, Lee S, Hong GR. Benign primary cardiac neoplasm with intense FDG uptake. Eur Heart J Cardiovasc Imaging. 2015;16:538. https://doi.org/10.1093/ehjci/jev020.

Billet S, Lavie-Badie Y, Hitzel A, Lairez O. What is the role of ¹⁸F-FDG uptake intensity in suspected atrial myxoma exploration? J Nucl Cardiol. 2018;25:1861–2. https://doi.org/10.1007/s12350-017-1094-6.

Liu E, Zhang X, Sun T, Chen Z, Dong H, Liu C, et al. Primary cardiac fibroma with persistent left superior vena cava in a young adult: contrast-enhanced CT and ¹⁸F-FDG PET/CT finding. J Nucl Cardiol. 2019. https://doi.org/10.1007/s12350-019-01825-6.

10.

Williams G, Kolodny GM. Suppression of myocardial ¹⁸F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. AJR. 2008;190:W151–6. https://doi.org/10.2214/AJR.07.2409.

11.

Harisankar CNB, Mittal BR, Agrawal KL, Abrar ML, Bhattacharya A. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake. J Nucl Cardiol. 2011;18:926–36. https://doi.org/10.1007/s12350-011-9422-8.CrossRefPubMed

12.

Demeure F, Hanin FX, Bol A, Vincent MF, Pouleur AC, Gerber B, et al. A randomized trial on the optimization of ¹⁸F-FDG myocardial uptake suppression: implications for vulnerable coronary plaque imaging. J Nucl Med. 2014;55:1629–35. https://doi.org/10.2967/jnumed.114.138594.

13.

Wicks EC, Menezes LJ, Barnes A, Mohiddin SA, Sekhri N, Porter JC, et al. Diagnostic accuracy and prognostic value of simultaneous hybrid ¹⁸F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging. 2018;19:757–67. https://doi.org/10.1093/ehjci/jex340.

14.

Ohira H, Tsujino I, Yoshinaga K. ¹⁸F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging. 2011;38:1773–83. https://doi.org/10.1007/s00259-011-1832-y.

15.

Ishida Y, Yoshinaga K, Miyagawa M, Moroi M, Kondoh C, Kiso K, et al. Recommendations for ¹⁸F-fluorodeoxyglucose positron emission tomography imaging for cardiac sarcoidosis: Japanese Society of Nuclear Cardiology recommendations. Ann Nucl Med. 2014;28:393–403. https://doi.org/10.1007/s12149-014-0806-0.

16.

Kumita S, Yoshinaga K, Miyagawa M, Momose M, Kiso K, Kasai T, et al. Recommendations for ¹⁸F-fluorodeoxyglucose positron emission tomography imaging for diagnosis of cardiac sarcoidosis-2018 update: Japanese Society of Nuclear Cardiology recommendations. J Nucl Cardiol. 2019;26:1414–33. https://doi.org/10.1007/s12350-019-01755-3.

17.

Delbeke D, Coleman RE, Guiberteau MJ, Brown ML, Royal HD, Siegel BA, et al. Procedure guideline for tumor imaging with ¹⁸F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885–95.

18.

Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181–200. https://doi.org/10.1007/s00259-009-1297-4.

19.

Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.CrossRefPubMed

20.

Beyer T, Antoch G, Bockisch A, Stattaus J. Optimized intravenous contrast administration for diagnostic whole-body ¹⁸F-FDG PET/CT. J Nucl Med. 2005;46:429–35.

21.

Sparrow PJ, Kurian JB, Jones TR, Sivananthan MU. MR imaging of cardiac tumors. RadioGraphics. 2005;25:1255–76. https://doi.org/10.1148/rg.255045721.CrossRefPubMed

22.

Saponara M, Ambrosini V, Nannini M, Gatto L, Astolfi A, Urbini M, et al. ¹⁸F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. Ther Adv Med Oncol. 2018. https://doi.org/10.1177/1758835918793569.

23.

Lee SM, Kim TS, Lee JW, Kim SK, Park SJ, Han SS. Improved prognostic value of standardized uptake value corrected for blood glucose level in pancreatic cancer using F-18 FDG PET. Clin Nucl Med. 2011;36:331–6. https://doi.org/10.1097/RLU.0b013e31820a9eea.CrossRefPubMed

24.

Nozawa A, Rivandi AH, Kesari S, Hoh CK. Glucose corrected standardized uptake value (SUVgluc) in the evaluation of brain lesions with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2013;40:997–1004. https://doi.org/10.1007/s00259-013-2396-9.CrossRefPubMed

25.

Bucerius J, Hyafil F, Verberne HJ, Slart RH, Lindner O, Sciagra R, et al. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM) on PET imaging of atherosclerosis. Eur J Nucl Med Mol Imaging. 2016;43:780–92. https://doi.org/10.1007/s00259-015-3259-3.CrossRefPubMed

26.

Lawal IO, Mokoala KG, Popoola GO, Lengana T, Ankrah AO, Stoltz AC, et al. Impact of optimized PET imaging conditions on ¹⁸F-FDG uptake quantification in patients with apparently normal aortas. J Nucl Cardiol. 2019. https://doi.org/10.1007/s12350-019-01833-6.

27.

Zhang X, Xie Z, Berg E, Judenhofer MS, Liu W, Xu T, et al. Total-body dynamic reconstruction and parametric imaging on the uEXPLORER. J Nucl Med. 2019. https://doi.org/10.2967/jnumed.119.230565.

28.

Nensa F, Tezgah E, Poeppel TD, Jensen CJ, Schelhorn J, Köhler J, et al. Integrated ¹⁸F-FDG PET/MR imaging in the assessment of cardiac masses: a pilot study. J Nucl Med. 2015;56:255–60. https://doi.org/10.2967/jnumed.114.147744.

29.

Yaddanapudi K, Brunken R, Tan CD, Rodriguez ER, Bolen MA. PET-MR imaging in evaluation of cardiac and paracardiac masses with histopathologic correlation. JACC Cardiovasc Imaging. 2016;9:82–5. https://doi.org/10.1016/j.jcmg.2015.04.028.

30.

Shao D, Wang SX, Liang CH, Gao Q. Differentiation of malignant from benign heart and pericardial lesions using positron emission tomography and computed tomography. J Nucl Cardiol. 2011;18:668–77. https://doi.org/10.1007/s12350-011-9398-4.CrossRefPubMed

31.

Zhu D, Yin S, Cheng W, Luo Y, Yang D, Lin K, et al. Cardiac MRI-based multi-modality imaging in clinical decision-making: preliminary assessment of a management algorithm for patients with suspected cardiac mass. Int J Cardiol. 2016;203:474–81. https://doi.org/10.1016/j.ijcard.2015.09.021.CrossRefPubMed

32.

Grebenc ML, Rosado-de-Christenson ML, Green CE, Burke AP, Galvin JR. Cardiac myxoma: imaging features in 83 patients. Radiographics. 2002;22:673–89.CrossRefPubMed

33.

Haji K, Nasis A. Radiological characteristics of atrial myxoma in Cardiac Computed Tomography. J Cardiovasc Comput Tomogr. 2017;11:234–6. https://doi.org/10.1016/j.jcct.2017.02.002.CrossRefPubMed

34.

Burke AP, Virmani R. Cardiac myxoma. A clinicopathologic study. Am J Clin Pathol. 1993;100:671–80. https://doi.org/10.1093/ajcp/100.6.671.CrossRefPubMed

35.

Hoffmeier A, Sindermann JR, Scheld HH, Martens S. Cardiac tumors--diagnosis and surgical treatment. Dtsch Arztebl Int. 2014;111:205–11. https://doi.org/10.3238/arztebl.2014.0205.CrossRefPubMedPubMedCentral

36.

Shin W, Choe YH, Kim SM, Song IY, Kim SS. Detection of cardiac myxomas with non-contrast chest CT. Acta Radiol. 2014;55:273–8. https://doi.org/10.1177/0284185113496561.CrossRefPubMed

37.

Mayer F, Aebert H, Rudert M, Königsrainer A, Horger M, Kanz L, et al. Primary malignant sarcomas of the heart and great vessels in adult patients — a single-center experience. The Oncologist. 2007;12:1134–42.CrossRefPubMed

38.

Look Hong NJ, Pandalai PK, Hornick JL, Shekar PS, Harmon DC, Chen Y-L, et al. Cardiac angiosarcoma management and outcomes: 20-year single-institution experience. Ann Surg Oncol. 2012;19:2707–15.CrossRefPubMed

39.

Liu C, Zhao Y, Yin Z, Hu T, Ren J, Wei J, et al. Right atrial epithelioid angiosarcoma with multiple pulmonary metastasis confirmed by multimodality imaging-guided pulmonary biopsy. Medicine (Baltimore). 2018;97(30):e11588. https://doi.org/10.1097/MD.0000000000011588.

40.

Guo W, Hao B, Chen H-J, Zhao L, Luo Z-M, Wu H, et al. PET/CT-guided percutaneous biopsy of FDG-avid metastatic bone lesions in patients with advanced lung cancer: a safe and effective technique. Eur J Nucl Med Mol Imaging. 2017;44:25–32. https://doi.org/10.1007/s00259-016-3455-9.CrossRefPubMed

Title: Combined PET/CT with thoracic contrast-enhanced CT in assessment of primary cardiac tumors in adult patients
Authors: En-Tao Liu
Tao-Tao Sun
Hao-Jian Dong
Si-Yun Wang
Ze-Rui Chen
Chao Liu
Dan Shao
Zhou-Yang Lian
Qiu Xie
Shu-Xia Wang
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Cardiac Tumor
Cardiac Tumor
Published in: EJNMMI Research / Issue 1/2020
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-020-00661-x

At a glance: The STEP trials

Springer Medicine

Combined PET/CT with thoracic contrast-enhanced CT in assessment of primary cardiac tumors in adult patients

Abstract

Background

Methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Impaired brain glucose metabolism and presynaptic dopaminergic functioning in a mouse model of schizophrenia

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake

Brain SPECT perfusion and PET metabolism as discordant biomarkers in major depressive disorder

Standardized image quality for 68Ga-DOTA-TATE PET/CT

Human adult and adolescent biodistribution and dosimetry of the synaptic vesicle glycoprotein 2A radioligand 11C-UCB-J

FDG PET versus CT radiomics to predict outcome in malignant pleural mesothelioma patients